News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Annual General Meeting of Active Biotech AB (BTPC)



5/17/2013 10:21:40 AM

LUND, SWEDEN--(Marketwired - May 16, 2013) -

The Annual General Meeting of Active Biotech was held on May 15, 2013.

In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.

In accordance with the Election Committee's proposal, the Board members Mats Arnhög, Peter Hofvenstam, Magnhild Sandberg, Peter Sjöstrand and Peter Thelin were re-elected. Rolf Kiessling was elected as a new Board member. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board. KPMG AB was re-elected as auditors.

Furthermore, in accordance with the Election Committee's proposal, the Meeting resolved that the Election Committee shall be composed of representatives for the three largest owners, as per the end of September, 2013, as well as the Chairman of the Board.

The Meeting approved the Board's proposal concerning guidelines for remuneration to the President and other senior executives. The guidelines essentially conform to the principles applied to date.

In accordance with the Board's proposal, the Meeting resolved to authorize the Board, for a period that does not extend past the date of the next Annual General Meeting, to resolve on the issue of not more than seven million new shares and/or convertibles with the corresponding dilution effect, with or without pre-emptive rights for the company's shareholders.

Lund, May 16, 2013

Active Biotech AB (publ)

Tomas Leanderson

President and CEO

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod for prostate cancer and ANYARA primarily for the treatment of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. The company also has one additional project in clinical development, the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 08:30 a.m. CET on May 16, 2013.

Annual General Meeting of Active Biotech AB: http://hugin.info/1002/R/1701975/562166.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1701975]


Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES